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Tobacco smoking and alcohol consumption are well-established risk factors for head and neck cancer. The prognostic role of
smoking and alcohol intake at diagnosis have been less well studied. We analysed 1,393 people prospectively enrolled into the
Head and Neck 5000 study (oral cavity cancer, n5403; oropharyngeal cancer, n5660; laryngeal cancer, n5330) and followed up
for a median of 3.5 years. The primary outcome was all-cause mortality. We used Cox proportional hazard models to derive mini-
mally adjusted (age and gender) and fully adjusted (age, gender, ethnicity, stage, comorbidity, body mass index, HPV status,
treatment, education, deprivation index, income, marital status, and either smoking or alcohol use) mortality hazard ratios (HR)
for the effects of smoking status and alcohol intake at diagnosis. Models were stratified by cancer site, stage and HPV status. The
fully-adjusted HR for current versus never-smokers was 1.7 overall (95% confidence interval [CI] 1.1, 2.6). In stratified analyses,
associations of smoking with mortality were observed for oropharyngeal and laryngeal cancers (fully adjusted HRs for current
smokers: 1.8 (95% CI50.9, 3.40 and 2.3 (95% CI50.8, 6.4)). We found no evidence that people who drank hazardous to harmful
amounts of alcohol at diagnosis had a higher mortality risk compared to non-drinkers (HR51.2 (95% CI50.9, 1.6)). There was no
strong evidence that HPV status or tumour stage modified the association of smoking with survival. Smoking status at the time of
a head and neck cancer diagnosis influenced all-cause mortality in models adjusted for important prognostic factors.
Head and neck cancers (HNCs) are a heterogeneous group
of tumours that arise from the mucosal epithelium of the
upper aerodigestive tract. Collectively, they represent the
sixth leading cause of cancer worldwide.1 Within the UK,
HNC incidence has increased by almost a quarter in the last
decade, with an estimated annual burden of 11,400 new
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cases.2 Since the early 1990s, oropharyngeal cancers (OPCs,
tonsil and base of tongue) have seen the biggest rise of any HNC,
with incidence rates more than doubling.3 In contrast, there has
been a 20% decrease in the incidence of laryngeal cancers in the
same period,4 though rates have levelled off more recently.5
Lifestyle factors play an important role in the aetiology of
these cancers.6 Around 75% of HNCs have been attributed to
the combined effects of tobacco and alcohol use.7 Human
papillomavirus (HPV) infection, predominantly HPV-16
infection, is also recognised as a primary risk factor for
OPCs, especially in younger age groups.8
Despite an overall decline in HNC mortality rates,3 survival
remains poor. The overall 5-year survival rate is around 50%,
but ranges from 33% for hypopharyngeal cancers to 60% for
laryngeal cancers.9 People with HPV-positive oropharyngeal
tumours have consistently demonstrated improved survival
compared to their HPV-negative counterparts, despite the fact
that they are frequently diagnosed at a later tumour stage.10
This is largely due to improved therapeutic response.8 People
with HPV-positive OPCs also tend to have distinct risk factor
proﬁles, including higher socioeconomic status and a lower
comorbidity,11 which may favour survival.
Although tobacco and alcohol drinking are responsible for
the majority of new HNC cases, the prognostic role of smok-
ing status and alcohol intake at the time of cancer presenta-
tion remains unclear, especially for people with HPV-
associated oropharyngeal tumours. In general, smoking and
heavy alcohol use are both related to increased mortality risk,
but estimates of the magnitude of the effects in this popula-
tion are hugely inconsistent. Moreover, it has yet to be estab-
lished whether smoking and alcohol use provide any
additional prognostic information beyond the tumour, node,
metastasis (TNM) staging system, which currently forms the
basis for clinical decision making in people with HNC.
In general, the HNC literature describes a dose-dependent
increase in mortality risk with increasing exposure to tobacco
pre-diagnosis.12–19 Studies have frequently been undertaken in
single cancer sites, however, typically the larynx or orophar-
ynx.17–19 Where studies have included multiple sites, analyses
have rarely stratiﬁed on this. Both factors may help explain why
estimates of the effect of smoking status on HNC survival have
varied so considerably. In addition to this, studies have fre-
quently been unable to adjust for important prognostic factors,
such as comorbidity,13–15 body mass index13,15,17,18 or HPV sta-
tus,12–15 often because they were conducted retrospectively.
Evidence of an association between pre-treatment alcohol
use and HNC mortality risk is conﬂicting. Some studies
report an inverse association between alcohol intake and sur-
vival,13,19–21 whilst others have found little or no evidence of
an effect.17,22 Consequently, it is unclear whether any associa-
tion of alcohol consumption with HNC cancer mortality is
genuine, or the result of residual confounding by smoking
(or other factors). Recently, it was suggested that the effects
of alcohol intake on HNC survival may differ by treatment
method and primary site,21 but this study only included 427
individuals from a single cancer centre in Japan, emphasising
the need for further research in this area.
An improved understanding of the prognostic signiﬁcance
of drinking and smoking status by site could help improve
HNC outcome prediction. This could in turn help inform the
lifestyle advice clinicians give to people upon a diagnosis of
HNC. In the present study, we used data collected as part of
a large, prospective study of over 5,500 people with HNC
from across 76 UK sites (Head and Neck 5000),23 to examine
the effect of smoking status and alcohol intake on survival in
different cancer sites. To our knowledge, this is the largest
study of its kind. Larger sample sizes generally lead to
increased precision, and therefore our results are arguably the
most accurate estimates of the effects of smoking status and
alcohol intake at diagnosis on HNC mortality to date. Fur-
thermore, given the wealth of clinical, biological and lifestyle
data available, owing to the prospective study design, we
were able to investigate possible interactions between smok-
ing, alcohol and HPV status in determining mortality risk.
Methods
Study population
The study population included individuals enrolled in the
Head and Neck 5000 clinical cohort study. Full details of the
study methods and population are described in detail else-
where.23 Brieﬂy, 5,511 people with a new HNC diagnosis
were recruited from 76 centres across the UK between April
2011 and December 2014. At the time of recruiting, there
were approximately 180 HNC centres nationally; 78 were
approached. Recruitment rates to the study varied by centre,
from around 20% to around 90% of eligible HNC cases.
Overall, we estimate that when all study centres were open,
the study captured a third of all incident cases in the UK.
Individuals were recruited before they started treatment,
unless their treatment was their diagnostic procedure. At
What’s new?
Smoking and alcohol use are risk factors for developing head-and-neck cancer (HNC) and are known to influence mortality in
general. However, the prognostic role of smoking status and alcohol intake at time of diagnosis on HNC survival is less clear.
In this study, the authors provide a comprehensive, prospective analysis of mortality risk in different tumour sites, adjusting
for important prognostic factors such as stage, comorbidity, and HPV infection. These results may provide insight to inform
and improve prediction of clinical outcomes.
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baseline, 5,474 (99%) data capture forms and 4,099 (74%)
health and lifestyle questionnaires were completed.24 Baseline
blood samples were obtained from 4,676 (85%) individuals. Full
ethical approval was granted by The South West – Frenchay
Regional Ethics Committee granted (ref: 10/H0107/57).
Baseline data collection
Participants were asked to complete three self-administered
questionnaires at baseline, which included questions on social
and economic circumstances, lifestyle behaviours, general
health and past sexual behaviours.23,25 Research nurses col-
lected a blood sample from all consenting participants.
Samples were frozen and stored at 2808C in the Avon Lon-
gitudinal Study of Parents and Children (ALSPAC) bio-
sample repository (http://www.bristol.ac.uk/alspac/). At each
site, information on stage at diagnosis, tumour stage, treat-
ment and various other clinical and pathologic prognostic
variables was abstracted from participants’ medical records.
Diagnoses were coded using the International Classiﬁcation
of Diseases (ICD) version 10.26 Clinical staging of the tumour
was based on the American Head and Neck Society TNM
staging of HNC.27
Assessment of tobacco and alcohol exposure
Detailed information on tobacco and alcohol history was
obtained at baseline via the self-reported questionnaire. Par-
ticipants were asked about their current smoking and drink-
ing status and their use of tobacco and alcohol products
pre-diagnosis.25 Smoking status was deﬁned as “current,”
“former” or “never.” Former smokers were deﬁned as having
smoked at least one cigarette a day for a period of at least a
year. Never smokers were deﬁned as having never smoked at
least one daily cigarette during a whole year. The question-
naire differentiated between use of cigarettes, hand-rolled cig-
arettes, cigars and smokeless tobacco. Respondents were
asked to report their average weekly alcohol consumption of
a range of alcoholic beverage types before they became ill.
Assessment of HPV status
HPV serologic testing was conducted at the German Cancer
Research Center (DKFZ, Heidelberg, Germany) using gluta-
thione S-transferase multiplex assays.28 Plasma was analysed
for antibodies against the HPV16 E6 oncoprotein (a marker
of HPV-transformed tumour cells29,30), using a median ﬂuo-
rescence intensity (MFI) cut-off of 1,000 MFI.31 The detec-
tion of antibodies against HPV early proteins in serum has
been shown to be highly sensitive and speciﬁc for HPV16-
driven OPSCC, and consequently provides a good surrogate
marker in the absence of appropriate histologic specimens.32
Study follow-up
Nurses at each site extracted up-to-date treatment and cancer
recurrence information from participants’ medical records.23
All participants were ﬂagged with NHS Digital (formerly the
Health and Social Care Information Centre (HSCIC)) for
ongoing notiﬁcation of deaths and provision of information
recorded on the death certiﬁcate.
Statistical analysis
All analyses were performed using the data release
H&N024_H&N dataset_v2.3.
The included population. The study involved participants
with cancers of the oral cavity, oropharynx and larynx (C01-
C06; C09-C10; C32).
Defining exposure. From the questionnaire data, we derived
an average intake of alcohol consumption in units per week.
Baseline drinking categories were then deﬁned as none, moder-
ate (men and women drinking <14 units/week), hazardous
(men consuming 14–50 units/week; women consuming 14–35
units/week) and harmful (men consuming >50 units/week;
women consuming >35 units/week), where one unit of
alcohol5 8 g/10 mL ethanol.33 Smoking categories were consis-
tent with those of the questionnaire (never, former and current).
Defining outcome. The outcome of interest was death from
any cause. Follow-up for survival analysis was deﬁned as the
time in years from study enrolment to date of death from
any cause or the date of censorship (i.e., the last date of fol-
low-up). We only included all-cause deaths in the current
analysis as assignment of death as being due to HNC on
death certiﬁcates is subject to misattribution bias.34
Descriptive analysis. Baseline descriptive data were stratiﬁed
by tumour site and HPV status (oropharyngeal only). The
v
2-test was used to compare the distribution of variables
between groups. Kaplan–Meier survival curves were plotted
to visualize survival probabilities, and differences in survival
between tumour sites in relation to smoking and alcohol sta-
tus were compared using the log-rank test.
Missing data. Data were missing for smoking status, alcohol
intake and the following covariates: body mass index (BMI),
tumour stage, treatment group*, comorbidity†, ethnicity,
annual household income, Index of Multiple Deprivation
(IMD‡),35 highest education level obtained and marital status.
Missing values were imputed using the ICE package for mul-
tiple chained equations in STATA.36 Twenty imputed data-
sets were generated for each tumour site and were combined
using Rubin’s rule to obtain valid statistical inferences.37
Imputation models included the event indicator, the Nelson–
*Refers to the intent of the cancer care plan for the patient’s head and neck
cancer at the point of diagnosis e.g. radiotherapy or chemotherapy.
†Comorbidity was measured using the Adult Co-morbidity Evaluation
(ACE-27) assessment tool. Categories were deﬁned as “mild-“, “moderate”-,
and “severe decompensation”,
‡IMD is the ofﬁcial measure of relative deprivation ranks every small area
(or neighbourhood) in England from 1 (most deprived area) to 32,844 (least
deprived area).
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Aalen estimator of the cumulative hazard,38 the tobacco and
alcohol exposure variables, in addition to the confounders
listed above.
Survival analysis. The primary analyses included complete
cases only i.e. participants with complete data for confound-
ers used in the adjusted models and information on smoking
and alcohol consumption. Cox proportional hazards models,
stratiﬁed by tumour site, stage and HPV status, were used to
examine the associations of baseline smoking status and alco-
hol intake with survival. Only oropharyngeal cases were con-
sidered in the HPV stratiﬁed models because the role of
HPV in tumours outside the oropharynx is uncertain, as is
the ability of serology to detect HPV driven tumours in other
anatomical sites. Hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) for mortality were calculated for each category
of smoking and drinking, using never-smokers and non-
drinkers as the reference groups. The proportional hazard
assumption was tested by plotting scaled Schoenfeld’s resid-
uals against survival time. Unadjusted Kaplan–Meier graphs
were plotted to compare overall survival between cancer sites
and between HPV seronegative and HPV seropositive cancers.
Minimally adjusted models included age and gender. Fully
adjusted models included the following variables: clinical
(tumour stage, BMI, comorbidity, treatment intent and
HPV status), sociodemographic (education, annual household
income, IMD and marital status, and ethnicity) and behav-
ioural. Models evaluating the effects of smoking included
adjustment for alcohol, whereas models evaluating the effects
of alcohol included adjustment for smoking. To account for
unobserved heterogeneity in recruitment centres, we ﬁtted a
Cox model with a shared frailty term (with gamma distribu-
tion). The signiﬁcance of the frailty component was tested
using a likelihood-ratio test. To allow assessment of the effect
of controlling for potential confounders, we qualitatively
compared minimally adjusted with fully adjusted models.
As a sensitivity analysis, we performed the same cox
regression models in the imputed dataset. Results, stratiﬁed
by tumour site and HPV status can be found in Supporting
Information Tables 6 and 7.
We further investigated potential interactions between: (i)
tumour stage and smoking, (ii) tumour stage and alcohol
consumption, (iii) HPV status and smoking, (iv) HPV status
and alcohol consumption and (v) smoking and alcohol
intake, by ﬁtting an interaction term in the models and using
a likelihood ratio test. As above, HPV analyses were restricted
to the subset of participants with oropharyngeal tumours.
All reported p-values are two-sided, with a5 0.05. All
analyses were conducted using Stata v15 (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station, TX:
StataCorp LP).
Results
Baseline characteristics of study population
The raw dataset included 5,369 individuals with HNC (Fig. 1).
Of these, 4,276 had cancers of the oral cavity (n5 1,296),
oropharynx (n5 1,910) and larynx (n5 1,070). After selecting
participants with complete data, the analytic sample consisted
of 1,393 individuals (oral cavity n5 403; oropharynx n5 660;
larynx n5 330).
Descriptive characteristics of the sample, stratiﬁed by
tumour site and HPV status, are presented in Tables 1 and 2
(Supporting Information Tables 1 and 2 for participants
included in the imputed analysis). There were differences
across tumour groups with respect to gender, age, stage,
HPV status, comorbidity, smoking status, education level,
annual household income, IMD quintile and marital status
across tumour groups (Table 1). There was no strong evi-
dence of a difference in the amount of alcohol consumed per
week (p for trend5 0.739; Table 1). At the time of diagnosis,
the proportion of former or current smokers was 72.7%,
70.0% and 90.6% in the oral cavity, oropharyngeal and laryn-
geal cancer groups, respectively. Smoking and drinking histo-
ries were comparable for participants included in the
imputed analysis (Supporting Information Table 1).
The proportion of OPCs that were HPV-positive was
73%. People with HPV-positive tumours were less likely
to be current smokers (6.4% compared to 36.5% in the
HPV-negative group; p trend <0.001). There was evidence
of a difference in alcohol consumption between groups
(p trend5 0.052), with a higher proportion of hazardous to
harmful drinkers in the HPV-negative group.
Missing data
The distribution of missing data for all participants with can-
cers of the oral cavity, oropharynx and larynx (n5 4,276),
stratiﬁed by site and HPV status, are shown in Supporting
Information Tables 3 and 4. Gender and age data were avail-
able for all participants. BMI data were missing for 41.9%
overall (as height and weight measurements were not rou-
tinely collected at the start of the study). Smoking and
Figure 1. Flow of head and neck 5000 participants through the study.
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Table 1. Baseline descriptive characteristics of participants, stratified by tumour site (n51,393)
Oral Cavity
(n5403)
Oropharynx
(n5660)
Larynx
(n5330)
Characteristic N % N % N % Total p values1
Survival status N/A
Alive 288 71.50% 542 82.10% 248 75.20% 1,078
Died 115 28.50% 118 17.90% 82 24.80% 315
Gender <0.001
Male 247 61.30% 539 81.70% 278 84.20% 1,064
Female 156 38.70% 121 18.30% 52 15.80% 329
Age group <0.001
<50 66 16.40% 93 14.10% 17 5.20% 176
50–64 170 42.20% 400 60.60% 125 37.90% 695
65–79 138 34.20% 153 23.20% 159 48.20% 450
801 29 7.20% 14 2.10% 29 8.80% 72
Ethnicity group 0.005
White 392 97.30% 656 99.40% 328 99.40% 1,376
Non-white 11 2.70% 4 0.60% 2 0.60% 17
TNM staging <0.001
Low 252 62.50% 93 14.10% 227 68.80% 572
High 151 37.50% 567 85.90% 103 31.20% 821
Serum HPV status <0.001
Negative 392 97.30% 178 27.00% 323 97.90% 893
Positive 11 2.70% 482 73.00% 7 2.10% 500
Comorbidity <0.001
None 177 43.90% 360 54.50% 138 41.80% 675
Mild 138 34.20% 207 31.40% 111 33.60% 456
Moderate/severe 88 21.80% 93 14.10% 81 24.50% 262
BMI 0.002
<18.5 14 3.50% 16 2.40% 13 4.00% 43
18.5–24.9 179 45.10% 220 33.50% 115 35.40% 514
25–29.9 133 33.50% 275 41.90% 128 39.40% 536
301 71 17.90% 146 22.20% 69 21.20% 286
Treatment group <0.001
Surgery only 314 77.90% 59 8.90% 75 22.70% 448
Surgery1 adjunct 61 15.10% 130 19.70% 22 6.70% 213
Chemorad only 6 1.50% 395 59.80% 49 14.80% 450
Radio only 17 4.20% 70 10.60% 182 55.20% 269
Palliative/supportive 5 1.20% 6 0.90% 2 0.60% 13
Smoking <0.001
Never 110 27.30% 198 30.00% 31 9.40% 339
Former 197 48.90% 366 55.50% 230 69.70% 793
Current 96 23.80% 96 14.50% 69 20.90% 261
Alcohol consumption 0.739
Non-drinker 119 29.50% 175 26.50% 92 27.90% 386
Moderate 84 20.80% 156 23.60% 70 21.20% 310
Hazardous to harmful 200 49.60% 329 49.80% 168 50.90% 697
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alcohol data were missing for 29.0% and 30.0% of partici-
pants, respectively. Gender, age, stage, comorbidity and treat-
ment group were comparable in people with and without
missing smoking and alcohol data (Supporting Information
Table 5). Those individuals with missing exposure data were
more likely to live in deprived areas (high depriva-
tion5 50.4% vs. 37.2% in people with smoking and alcohol
data.
Survival analysis
We found no violations of the proportionality assumption for
any of the covariates included in the multivariable models.
There were 315 deaths (oral cavity n5 115 (28.5%); orophar-
ynx n5 118 (17.9%); larynx n5 82 (24.8%)) during a median
follow-up time of 3.5 years (25% IQR5 2.9 years; 75%
IQR5 4.2 years). The proportion of deaths across tumour
groups was comparable in the imputed analysis (32.9%,
24.0% and 27.7% for oral cavity, oropharyngeal and laryngeal
cancers respectively). Kaplan–Meier estimates of survival by
smoking and alcohol intake at diagnosis, stratiﬁed by tumour
site and HPV status, are presented in Supporting Information
Figures 1 and 2.
Inclusion of a frailty term did not improve the propor-
tional hazards model (p values for the one-sided likelihood
ratio test5 0.13), suggesting that there is no heterogeneity in
effect-estimates by recruitment centre.
Smoking status and survival. For all cancer sites combined
(n5 1,393), there was strong evidence of an association
between smoking status at diagnosis and survival. Compared
to never smokers, the HR for current smokers was 3.0 (95%
CI5 2.1, 4.3, 3.6; p-trend <0.001) in the minimally adjusted
model and attenuated to 1.71 (95% CI5 1.1, 2.6; p-trend 5
0.001) in the fully adjusted model (Table 3). For former
smokers, the HR was 1.6 (95% CI5 1.2, 2.3; p-trend <0.001)
in the minimally adjusted model and attenuated to 1.4 (95%
CI5 1.0, 2.0; p-trend 0.001) on full adjustment.
The associations of smoking status with survival were pre-
sent for oropharyngeal and laryngeal cancer groups in the
subgroup analysis. In the OPC group, the HR for current
smokers was 3.9 (95% CI5 2.3, 6.7; p-trend <0.001) in the
minimally adjusted model and 1.8 (95% CI5 0.9, 3.4; p-trend
0.008) in the fully adjusted model (Table 3); for people
with laryngeal cancers, the respective HRs were 3.2 (95%
CI5 1.2, 8.4; p-trend <0.001) and 2.3 (95% CI5 0.8, 6.4;
p-trend5 0.011).
Results of the imputed analysis (n5 4,276) were compara-
ble to those of the complete case analysis. In minimally
adjusted models, the hazard ratio was 2.9 (95% CI5 2.3, 3.7)
and 1.6 (95% CI5 1.3, 1.9; p for trend5<0.001) for current
and former smokers, respectively. In fully adjusted models,
the corresponding hazard ratios were 1.6 (95% CI5 1.2, 2.1)
and 1.3 (95% CI5 1.1, 1.6; p for trend5<0.001) (Support-
ing Information Table 6). A similar pattern of association
was seen in the stratiﬁed analysis.
Alcohol intake and survival. In the minimally adjusted
model, the hazard ratio for hazardous to harmful drinkers
Table 1. Baseline descriptive characteristics of participants, stratified by tumour site (n51,393) (Continued)
Oral Cavity
(n5403)
Oropharynx
(n5660)
Larynx
(n5330)
Characteristic N % N % N % Total p values1
Highest education level 0.005
School education 181 44.90% 284 43.00% 179 54.20% 644
College 142 35.20% 243 36.80% 110 33.30% 495
Degree 80 19.90% 133 20.20% 41 12.40% 254
Annual household income <0.001
<£18.000 200 49.60% 223 33.80% 184 55.80% 607
£18.000 to £34.999 114 28.30% 209 31.70% 94 28.50% 417
£35.0001 89 22.10% 228 34.50% 52 15.80% 369
IMD group 0.005
Low deprivation 184 45.70% 288 43.60% 115 34.80% 587
Moderate deprivation 83 20.60% 155 23.50% 70 21.20% 308
High deprivation 136 33.70% 217 32.90% 145 43.90% 498
Marital status 0.021
Single 51 12.70% 65 9.80% 39 11.80% 155
In a relationship 260 64.50% 485 73.50% 218 66.10% 963
Separated/divorced/widow 92 22.80% 110 16.70% 73 22.10% 275
N5 number of participants.
1p values for trend.
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compared to non-drinkers was 1.2 (95% CI5 0.9, 1.6; p-
trend5 0.072) (Table 3). On full adjustment, there was no
evidence for an increase in mortality risk (HR5 1.1 (95%
CI5 0.9, 1.5; p-trend5 0.314). There was weak evidence to
suggest that moderate drinkers experienced improved survival
compared to non-drinkers in the minimally adjusted model
(HR5 0.8, 0.6, 1.1; p for trend5 0.072), but this association
was not robust to adjustment.
When models were stratiﬁed by tumour site, there was no
evidence of an association between alcohol consumption and
survival.
In the imputed analyses, a comparable pattern of associa-
tion between alcohol drinking and survival was observed
(minimally adjusted model: HR5 1.2 (95% CI5 1.0, 1.4) and
0.9 (95% CI5 0.7, 1.1; p for trend5<0.036) for hazardous/
harmful and moderate drinkers, respectively, fully adjusted:
HR5 1.1 (95% CI5 0.9, 1.3) and 0.9 (95% CI5 0.7, 1.1)
(Supporting Information Table 6).
Influence of tumour stage on the associations of smoking
and alcohol intake with survival. There were 572 people
with low stage tumours and 821 with high stage tumours in
the analysis. On full adjustment, the hazard of death for cur-
rent versus never-smokers was 2.3 in the low stage group
(95% CI5 1.1, 4.9; p for trend5 0.075), and 1.7 in the high
stage group (95% CI5 1.0, 2.8; p for trend5<0.004) (Table
4). There was no evidence of an association between the
amount of alcohol consumed at diagnosis and survival in
either the low or high stage subgroups.
Table 2. Baseline descriptive characteristics of participants with oro-
pharyngeal tumours, stratified by HPV status
HPV
negative
HPV
positive
Characteristic N % N % p value1
Survival status <0.001
Alive 120 67.40% 422 87.60%
Died 58 32.60% 60 12.40%
Gender 0.149
Male 139 78.10% 400 83.00%
Female 39 21.90% 82 17.00%
Age group 0.339
<50 29 16.30% 64 13.30%
50–64 98 55.10% 302 62.70%
65–79 46 25.80% 107 22.20%
801 5 2.80% 9 1.90%
Ethnicity group 0.298
White 176 98.90% 480 99.60%
Non-White 2 1.10% 2 0.40%
TNM staging <0.001
Low 43 24.20% 50 10.40%
High 135 75.80% 432 89.60%
Comorbidity <0.001
None 79 44.40% 281 58.30%
Mild 59 33.10% 148 30.70%
Moderate/severe 40 22.50% 53 11.00%
BMI <0.001
<18.5 10 5.60% 6 1.30%
18.5–24.9 81 45.50% 139 29.00%
25–29.9 62 34.80% 213 44.50%
301 25 14.00% 121 25.30%
Treatment group 0.001
Surgery only 20 11.20% 39 8.10%
Surgery1 adjunct 30 16.90% 100 20.70%
Chemorad only 95 53.40% 300 62.20%
Radio only 28 15.70% 42 8.70%
Palliative/supportive 5 2.80% 1 0.20%
Smoking <0.001
Never 25 14.00% 173 35.90%
Former 88 49.40% 278 57.70%
Current 65 36.50% 31 6.40%
Alcohol consumption 0.052
Non-drinker 43 24.20% 132 27.40%
Moderate 33 18.50% 123 25.50%
Hazardous to harmful 102 57.30% 227 47.10%
Highest education level 0.693
School education 78 43.80% 206 42.70%
Table 2. Baseline descriptive characteristics of participants with oro-
pharyngeal tumours, stratified by HPV status (Continued)
HPV
negative
HPV
positive
Characteristic N % N % p value1
College 68 38.20% 175 36.30%
Degree 32 18.00% 101 21.00%
Annual household
income
<0.001
<£18.000 87 48.90% 136 28.20%
£18.000 to £34.999 51 28.70% 158 32.80%
£35 000 1 40 22.50% 188 39.00%
IMD group 0.555
Low deprivation 74 41.60% 214 44.40%
Moderate deprivation 47 26.40% 108 22.40%
High deprivation 57 32.00% 160 33.20%
Marital status <0.001
Single 23 12.90% 42 8.70%
In a relationship 109 61.20% 376 78.00%
Seperated/divorced
/widow
46 25.80% 64 13.30%
N5 number of participants.
1p values for trend.
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Table 3. Association of smoking status and alcohol intake with mortality risk, stratified by tumour site (n51,393)
All sites (n51.393) Oral cavity (n5403) Oropharyngeal (n5660) Larynx (n5330)
HR Lower CI Upper CI p value1 HR Lower CI Upper CI p value1 HR Lower CI Upper CI p value1 HR Lower CI Upper CI p value1
Model 1
Smoking <0.001 0.036 <0.001 <0.001
Former 1.66 1.20 2.30 2.32 1.39 3.89 1.51 0.92 2.46 1.24 0.49 3.12
Current 3.03 2.12 4.32 1.91 1.06 3.44 3.93 2.30 6.73 3.23 1.24 8.41
Alcohol amount 0.072 0.186 0.486 0.616
Moderate 0.77 0.55 1.09 0.72 0.40 1.29 0.85 0.49 1.46 0.70 0.36 1.39
Hazardous/harmful 1.22 0.93 1.60 1.29 0.83 2.01 1.13 0.72 1.75 1.09 0.65 1.83
Model 2
Smoking <0.001 0.142 0.015 0.007
Former 1.48 1.06 1.06 2.28 1.35 3.85 1.25 0.76 2.06 1.10 0.43 2.78
Current 1.84 1.26 2.69 1.55 0.83 2.87 2.18 1.19 3.98 2.28 0.86 6.05
Alcohol amount 0.162 0.183 0.491 0.708
Moderate 0.77 0.54 1.08 0.76 0.42 1.38 0.86 0.49 1.49 0.62 0.31 1.24
Hazardous/harmful 1.15 0.88 1.50 1.40 0.89 2.21 1.06 0.68 1.66 1.00 0.59 1.71
Model 3
Smoking 0.001 0.081 0.045 0.010
Former 1.48 1.05 1.07 2.60 1.51 4.49 1.26 0.76 2.08 1.14 0.43 3.01
Current 1.82 1.22 1.70 1.70 0.27 3.34 1.82 0.96 3.47 2.40 0.85 6.78
Alcohol amount 0.160 0.092 0.315 0.665
Moderate 0.79 0.56 1.12 0.79 0.43 1.45 0.95 0.54 1.67 0.63 0.31 1.26
Hazardous harmful 1.17 0.89 1.53 1.44 0.91 2.30 1.19 0.75 1.88 1.04 0.61 1.80
Model 4
Smoking 0.001 0.145 0.049 0.011
Former 1.42 1.01 2.00 2.45 1.41 4.25 1.23 0.74 2.04 1.10 0.42 2.91
Current 1.71 1.14 2.55 1.55 0.78 3 07 1.79 0.93 3.43 2.25 0.80 6.39
Alcohol amount 0.314 0.164 0.355 0.960
Moderate 0 81 0.57 1.14 0.75 0.41 1.39 1.02 0.58 1.80 0.64 0.32 1.29
Hazardous/harmful 1.12 0.85 1.47 1.31 0.82 2. 12 1.20 0.75 1.90 0.97 0.56 1.67
Model 1 (minimally adjusted): adjusted for age and gender.
Model 2: additionally adjusted for clinical features (stage, treatment, comorbidity, BMI, HPV).
Model 3: additionally adjusted for social features (education, annual household income, IMD, marital status, ethnicity).
Model 4 (fully adjusted): additionally includes smoking or drinking.
HR5hazard ratio; CI5 confidence interval.
1p values for trend.
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In the imputed analysis, there was a 2.2-fold higher mor-
tality risk (95% CI5 1.4, 3.6; p-trend5<0.001) for current
versus never smokers in the low stage tumour group
(n5 1,701) compared to a 1.4-fold higher mortality risk
(95% CI5 1.1, 2.0; p< 0.007) in the high stage tumour group
(n5 2,562). The HRs for hazardous to harmful drinkers were
similar to those in the primary analyses (Supporting Informa-
tion Table 7).
Influence of HPV status on the associations of smoking and
alcohol intake with survival. Results of the HPV-stratiﬁed
analyses are presented in Table 5. In fully adjusted models
(n5 660), the HR for current versus never smokers was 1.3
(95% CI5 0.3, 5.1; p-trend5 0.481) in the HPV-negative
group (n5 178) and 2.1 (95% CI5 0.8, 5.3; p-trend5 0.263)
in the HPV-positive group (n5 482). The mortality hazards
for hazardous to harmful drinkers versus non-drinkers were
2.6 (95% CI5 1.2, 5.6; p-trend5 0.012) and 0.6 (95%
CI5 0.3, 1.1; p-trend5 0.160) in HPV-negative and HPV-
positive groups, respectively. Results of the imputed analyses
(n5 1,595) are presented in Supporting Information Table 8.
Here, there was evidence that current smokers were at increased
risk of death compared to non-smokers, regardless of HPV
status (fully adjusted HR5 1.9 (95% CI5 0.9, 4.1; p for
Table 4. Association of smoking status and alcohol intake with mortality risk, stratified by tumour stage (n51,393)
Low stage (n5572) High stage (n5821)
HR Lower CI Upper CI p value1 HR Lower CI Upper CI p value1
Model 1
Smoking <0.001
Former 2.02 1.05 3.86 1.65 1.13 2.41
Current 2.90 1.44 5.82 0.002 3.50 2.31 5.29
Alcohol amount 0.445
Moderate 0.67 0.35 1.30 0.75 0.50 1.12
Hazardous/harmful 1.45 0.90 2.34 0.074 1.08 0.78 1.50
Model 2
Smoking 0.005
Former 2.05 1.06 3.97 1.35 0.92 1.99
Current 2.38 1.16 4.90 0.052 1.75 1.11 2.75
Alcohol amount 0.619
Moderate 0.72 0.37 1.40 0.80 0.53 1.19
Hazardous/harmful 1.50 0.92 2.45 0.121 1.05 0.76 1.45
Model 3
Smoking 0.004
Former 2.15 1.09 4 23 1.40 0.94 2.09
Current 2.54 1.19 5.45 0.075 1.77 1.09 2.86
Alcohol amount 0.655
Moderate 0.71 0.36 1.40 0.81 0.54 1.23
Hazardous/harmful 1.58 0.96 2.60 0.086 1.04 0.75 1.46
Model 4
Smoking 0.004
Former 2.00 1.01 3.97 1.37 0.92 2.05
Current 2.29 1.06 4.94 0.075 1.70 1.04 2.77
Alcohol amount 0.904
Moderate 0.68 0.34 1.33 0.85 0.56 1.29
Hazardous/harmful 1.44 0.88 2.36 0.135 1.02 0.73 1.42
Model 1 (minimally adjusted): adjusted for age and gender.
Model 2: additionally adjusted for clinical features (stage, treatment, comorbidity, BMI).
Model 3: additionally adjusted for social features (education, annual household income, IMD, marital status, ethnicity).
Model 4 (fully adjusted): additionally includes smoking or drinking.
HR5 hazard ratio; CI5 confidence interval.
1p values for trend.
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trend5 0.070) and 2.0 (95% CI5 1.0, 4.0; p for trend5 0.049)
for HPV-negative and HPV-positive groups, respectively).
There was no strong evidence that HPV status modiﬁed
the association of smoking with survival in the sensitivity
analyses (p-interaction5 0.563). The effect of alcohol may
differ by HPV status (p-interaction5 0.024), but this may
be due to chance as the number of deaths was small (58 in
the HPV negative group and 60 in the HPV positive
group).
Interaction of tobacco and alcohol. We found no evidence
of an interaction between smoking and alcohol consumption on
survival (p-interaction5 0.233 in the fully adjusted model).
Discussion
Principle findings
The major ﬁnding of this large, prospective study is that, even
after adjusting for a wide-range of prognostic factors (con-
founders), smoking status at the time of a HNC diagnosis is
associated with worse survival. In fully adjusted models, cur-
rent smokers had around a 70% higher all-cause mortality
risk compared to people who had never smoked, whilst for-
mer smokers were over 40% more likely to die during follow-
up. Drinking behaviour around the time of diagnosis was not
associated with overall mortality risk in this analysis.
Our ﬁndings are in line with those of earlier studies,
which suggest that smoking at the time of a HNC diagnosis
Table 5. Association of smoking status and alcohol intake with mortality risk, stratified by HPV status (n5660)
HPV negative (n5178) HPV positive (n5482)
HR Lower CI Upper CI p value1 HR Lower CI Upper CI p value1
Model 1
Smoking 0.002 0.313
Former 3.02 0.91 10.05 1.08 0.61 1.89
Current 5.12 1.53 17.18 1.82 0.75 4.42
Alcohol amount 0.038 0.096
Moderate 0.70 0.26 1.90 0.89 0.46 1.71
Hazardous/harmful 1.84 0.92 3.65 0.60 0.33 1.12
Model 2
Smoking 0.188 0.271
Former 2.16 0.64 7.23 1.05 0.59 1.87
Current 2.58 0.75 8.91 1.88 0.77 4.61
Alcohol amount 0.016 0.093
Moderate 0.76 0.26 2.24 0.93 0.48 1.79
Hazardous/harmful 2.01 1.00 4.03 0.59 0.32 1.09
Model 3
Smoking 0.493 0.265
Former 2.30 0.67 7.96 1.03 0.57 1.85
Current 1.71 0.45 6.50 2.02 0.80 5.10
Alcohol amount 0.008 0.119
Moderate 1.19 0.38 3.76 0.90 0.46 1.77
Hazardous/harmful 2.82 1.34 5.91 0.57 0.30 1.11
Model 4
Smoking 0.481 0.263
Former 1.53 0.43 5.48 1.07 0.59 1.94
Current 1.30 0.33 5.14 2.06 0.81 5.25
Alcohol amount 0.012 0.160
Moderate 1.11 0.34 3.59 0.93 0.47 1.83
Hazardous/harmful 2.59 1.20 5.61 0.58 0.30 1.12
Model 1 (minimally adjusted): adjusted for age and gender.
Model 2: additionally adjusted for clinical features (stage, treatment, comorbidity, BMI).
Model 3: additionally adjusted for social features (education, annual household income, IMD, marital status, ethnicity).
Model 4 (fully adjusted): additionally includes smoking or drinking.
HR5 hazard ratio; CI5 confidence interval.
1p values for trend.
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may result in poorer clinical outcomes and reduced sur-
vival.12,13,15,39 Estimates of the size of the effect have varied
considerably however, ranging from a 2.4-fold higher all-
cause mortality risk in current versus never-smokers12 to an
almost ﬁvefold higher mortality risk in people with >60
pack-years of smoking versus never-smokers.13 There are a
number of possible explanations for this. First, much of the
evidence is based on retrospective analyses of population-
level cancer registries, which are often incomplete or incor-
rect.40 Consequently, studies have frequently been missing
information on important clinical and lifestyle factors such as
comorbidity, BMI and socioeconomic position, which could
potentially confound the association of smoking with sur-
vival. Those studies which have been conducted prospectively
are small—typically ﬁve hundred persons or fewer,12–14 and
as a result they have limited statistical power to detect an
accurate measure of the effect. Second, estimates have been
derived from different subpopulations of people, i.e. different
HNC sites or tumour stages, which are often not considered
separately. This could bias estimates of the effect of smoking
on survival if mortality risk is greater or lesser in certain
tumour groups.
With respect to alcohol consumption, the existing literature
is limited and conﬂicting. Our results support those of Duffy
et al. who found no difference in mortality risk between active
drinkers and non-drinkers after adjusting for a wider range of
confounders.12 In contrast to this however, Mayne et al.
reported a ﬁvefold increased mortality risk for persons who
drank >35 drinks per week compared to those who abstained.13
Both studies were relatively small (504 and 204 people, respec-
tively), and enrolled participants from either a single centre12 or
a single clinical trial,13 limiting their generalisability.
It is biologically plausible that, as well as being risk factors
for HNC, smoking could reduce survival following a diagno-
sis. One way in which smoking could inﬂuence survival is
through its effects on treatment response. A growing body of
evidence suggests that smokers have an increased risk of
treatment-related adverse events and poorer clinical outcomes
following radiotherapy, compared to non-smokers.41,42 The
biological mechanisms underpinning this association are not
fully understood, but increased tumour hypoxia, resulting
from increased carboxyhaemoglobin (the binding of carbon
monoxide to haemoglobin) in smokers, is a likely explana-
tion.43 In addition to this, it has been suggested that tobacco
reduces the efﬁcacy of radiotherapy through triggering a p53
mutation that could promote resistance to apoptosis.44 Smok-
ing is also known to effect inﬂammatory responses45 and
immune competence,46 which could increase the likelihood
of adverse clinical outcomes.
Strengths and limitations of the study
This study has several strengths. These include the prospec-
tive population-based cohort design, the relatively large sam-
ple size and our ability to adjust for multiple biological,
clinical and lifestyle covariates, including HPV. In addition to
this, we explored the risk of bias due to missing data by
employing a multiple imputation approach.47 Results of the
imputed analysis was broadly consistent with those of the
complete case analysis.
The study has several limitations. First, as in most previ-
ous studies, assessments of smoking and alcohol intake were
based on participants’ self-reports. Prior work has shown that
self-reports can often provide an inaccurate assessment of
tobacco and alcohol use, particularly in people who have
recently been diagnosed with cancer.48 This would most
likely result in an underestimation of the effects of smoking
and drinking on HNC survival.
Second, although we adjusted for several confounders in
our models, residual confounding by unmeasured or poorly
measured factors, such as a delay in receiving treatment or
other lifestyle factors related to smoking and drinking behav-
iours (e.g., physical activity and dietary intake), is possible.
Furthermore, it is possible that the individuals included in
the complete case analysis were different to those in the
imputed analysis, since those with missing smoking and alco-
hol data lived in more deprived areas overall. However, given
that results were comparable using both approaches, it seems
unlikely that the complete case analysis was biased by socio-
economic position.
Third, whilst the sample size was sufﬁcient for us to detect
the main effects of baseline smoking status and alcohol intake
on survival, it was insufﬁcient to examine interactions
between these two exposures and HPV in determining mor-
tality; it also limited our ability to investigate whether the
effects of smoking and drinking on survival were modiﬁed by
cancer site. This was because there were only a small number
of events (deaths) in each subgroup. We had no prior
hypotheses that smoking or alcohol intake would have a
greater or lesser effect on survival in any one cancer group
however, and therefore the analyses were exploratory by
design.
Fourth, we used HPV-speciﬁc antibody levels to identify
individuals with HPV-positive oropharyngeal tumours, but
the presence of HPV16 DNA is considered the gold standard
measure. Previous studies have conﬁrmed, however, that
detection of antibodies against E6 and E7 oncoproteins shows
good correlation with HPV DNA in the tumour tissue.32
Kreimer et al. showed that high HPV viral load increased the
odds of HPV16 E6 seropositivity 57-fold and HPV16 E7
seropositivity 26-fold. Moreover, HPV16 E6 antibodies have
also been shown to be independent favourable prognostic fac-
tors in OPCs.49,50 Some HPV-related OPCs are mediated by
other HPV genotypes, including HPV18 (1–8% of OPCs),
and less commonly HPV33, 235, 256 and 267.51 We only
considered HPV16 in the current analysis because 69% of the
1,910 participants with OPCs were HPV16 positive, com-
pared to only 2% who were HPV18 positive.
Finally, we were unable to examine whether baseline
smoking status and alcohol intake inﬂuenced cancer-speciﬁc
mortality as cause-speciﬁc mortality data were not available
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for all participants. Previous studies suggest that death from
non-cancerous causes (competing mortality) and second pri-
mary malignancies are important events in HNC52 and could
provide greater insight into the biological mechanisms that
underlie the associations of smoking and drinking with sur-
vival. The cause of death information on a death certiﬁcate is
often inaccurate however.53 Accuracy of all-cause mortality is
solely dependent on the number of deaths identiﬁed, and is
arguably a more reliable outcome measure.
Policy implications
Our results emphasise the importance of clinicians recording
information on peoples’ smoking status in their medical notes
at the time of diagnosis, to help identify those at risk of poor
survival. It is possible that smoking cessation and reduced alco-
hol consumption could reduce mortality in this population,
which highlights the need to take advantage of the “teachable
moment” that a cancer diagnosis presents.54 Clinicians rou-
tinely advise people with HNC to stop smoking, but our data
provides an impetus for health providers and policy makers to
ensure that this remains a focus of care.
Future research
There remain several unanswered questions concerning the
role of smoking status and alcohol use in HNC survival.
First, it is unclear whether the associations of smoking and
alcohol use at the time of diagnosis with survival vary in dif-
ferent tumour sites. In the current study, the mortality haz-
ard for current smokers was much lower in the oral cavity
cancer group than it was in the oropharyngeal and laryngeal
cancer groups, suggesting that tumour site may modify the
relationship between smoking status and survival. This ﬁnd-
ing needs to be validated in other HNC cohorts.
The second unanswered question is, what inﬂuence does
HPV have on the associations of tobacco and alcohol use with
survival? It has been shown that smoking increases the risk of
OPC, irrespective of HPV16 status,55 but evidence of an effect
of joint exposure on survival after diagnosis is conﬂicting. Some
studies report reduced survival in HPV-positive smokers com-
pared to their non-smoking counterparts,18 whilst others report
no difference in prognosis between HPV-positive smokers and
HPV-positive non-smokers.56 To the best of our knowledge, no
studies have compared the prognostic value of alcohol use in
people with HPV-positive versus HPV-negative OPCs. To ade-
quately address these questions, further well-designed studies in
people with oropharyngeal tumours are needed, which are large
enough to ensure that there is adequate power to detect an
interaction. Furthermore, HPV testing needs to be included,
where possible, in all future studies involving OPC cases.
The ﬁnal question is whether survival can be improved
with smoking cessation and reduced alcohol consumption after
diagnosis. Given that at least one-third of people with HNC
continue to smoke and 16% continue to drink hazardously57
after receiving the primary HNC diagnosis, this is an impor-
tant question to address. Few studies in the literature have
examined patterns of smoking and alcohol drinking after diag-
nosis, but there is some evidence to suggest beneﬁts of smok-
ing cessation in terms of response to radiation therapy and
reduced risk of second primary tumours.58 If smoking cessa-
tion and reduced alcohol consumption can improve survival
rates in this population, then pilot behavioural intervention tri-
als should be conducted to identify the most effective way of
supporting individuals to make and sustain changes.
An issue which is pertinent to all future research in this
area is the accurate measurement of smoking and alcohol use
in observational studies. As highlighted above, self-reported
intake is frequently unreliable, but recent advances in
genome-wide methylation proﬁling have permitted the identi-
ﬁcation of robust biomarkers of tobacco and alcohol expo-
sure,59,60 circumventing issues of reporting bias. Another
approach that could be used to obtain unbiased estimates of
the causal effects of tobacco and alcohol consumption on
HNC survival is Mendelian Randomization, whereby genetic
variants which modulate an observed risk factor are used as
a proxy measure for that exposure, eliminating problems of
confounding and reverse causation.61
Conclusions
In this large prospective clinical cohort of people with HNC we
showed that smoking status at the time of diagnosis is associ-
ated with poorer survival. Further research should explore
whether interventions that encourage smoking cessation or
reduced alcohol consumption result in improved outcomes.
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